Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Theralase Technologies Inc
(OP:
TLTFF
)
0.1511
+0.0101 (+7.16%)
Streaming Delayed Price
Updated: 10:58 AM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Theralase Technologies Inc
< Previous
1
2
3
Next >
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
February 05, 2024
Via
ACCESSWIRE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
January 15, 2024
Via
ACCESSWIRE
Theralase Release’s 3Q2023 Interim Financial Statements
November 29, 2023
Via
ACCESSWIRE
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023
Via
ACCESSWIRE
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
November 17, 2023
Via
ACCESSWIRE
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
October 23, 2023
Via
ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 16, 2023
Via
ACCESSWIRE
Theralase(R) Announces Brokered LIFE Financing
October 23, 2023
Via
ACCESSWIRE
Theralase(R) Files US Patent for Enhanced Immunotherapy
October 05, 2023
Via
ACCESSWIRE
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
September 29, 2023
Via
ACCESSWIRE
Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
September 27, 2023
Via
ACCESSWIRE
Theralase(R) Grants Stock Options
September 21, 2023
Via
ACCESSWIRE
Theralase(R) Closes Private Placement Equity Financing
September 07, 2023
Via
ACCESSWIRE
Theralase Release’s 2Q2023 Interim Financial Statements
August 29, 2023
Via
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement Equity Financing
June 30, 2023
Via
ACCESSWIRE
Theralase(R) Announces Appointment of New Independent Director
June 06, 2023
Via
ACCESSWIRE
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
May 30, 2023
Via
ACCESSWIRE
Theralase(R) Releases 1Q2023 Interim Financial Statements
May 30, 2023
Via
ACCESSWIRE
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
May 24, 2023
Via
ACCESSWIRE
Theralase Provides Update on Phase II Bladder Cancer Study
May 10, 2023
Via
ACCESSWIRE
Theralase Release FY2020 Audited Financial Statements
April 28, 2021
TORONTO, ON / ACCESSWIRE / April 28, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and...
From
Theralase Technologies Inc.
Via
AccessWire
Theralase(R) Releases Quarterly Newsletter
April 27, 2021
TORONTO, ON / ACCESSWIRE / April 27, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and...
From
Theralase Technologies Inc.
Via
AccessWire
Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
April 09, 2021
TORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and...
From
Theralase Technologies Inc.
Via
AccessWire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
